Business Wire - ARIAD Reports Tumor Regression With AP23573 As a Single Agent i
Posted on Thursday, September 30 @ 07:00:00 CDT by admin
September 30, 2004 -- CAMBRIDGE, Mass. -- Updated Phase 1 Clinical Results on Novel mTOR Inhibitor Presented at International Cancer Symposium ARIAD Pharmaceuticals, Inc.
Click Here to read the entire article...
|
| |
|